{"organizations": [], "uuid": "cc06b90b8f2ca4efd9ede60b63910fc4754badb7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180411.html", "section_title": "Archive News &amp; Video for Wednesday, 11 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/wilson-therapeut-ma-alexion-pharms/alexion-to-buy-swedish-biotech-wilson-therapeutics-for-855-mln-idUSL8N1RO12E", "country": "US", "domain_rank": 408, "title": "Alexion to buy Swedish biotech Wilson Therapeutics for $855 mln", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.978, "site_type": "news", "published": "2018-04-11T14:33:00.000+03:00", "replies_count": 0, "uuid": "cc06b90b8f2ca4efd9ede60b63910fc4754badb7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/wilson-therapeut-ma-alexion-pharms/alexion-to-buy-swedish-biotech-wilson-therapeutics-for-855-mln-idUSL8N1RO12E", "ord_in_thread": 0, "title": "Alexion to buy Swedish biotech Wilson Therapeutics for $855 mln", "locations": [], "entities": {"persons": [{"name": "wilson", "sentiment": "negative"}, {"name": "ben hirschler", "sentiment": "none"}, {"name": "susan fenton", "sentiment": "none"}], "locations": [{"name": "sweden", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "alexion", "sentiment": "negative"}, {"name": "alexion pharmaceuticals", "sentiment": "negative"}, {"name": "wilson therapeutics", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 11 (Reuters) - Alexion Pharmaceuticals said on Wednesday it had agreed to buy Swedenâ€™s Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million) to boost its line-up of rare disease drugs.\nThe U.S. group is acquiring the business through a tender offer worth 232 crowns per share.\n$1 = 8.3000 Swedish crowns Reporting by Ben Hirschler; Editing by Susan Fenton\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-11T14:33:00.000+03:00", "crawled": "2018-04-12T14:13:48.020+03:00", "highlightTitle": ""}